Literature DB >> 11451590

Involvement of activin in the regulation of bone metabolism.

R Sakai1, Y Eto.   

Abstract

Osteogenic activities of activin, a member of TGF-beta superfamily, have been shown in both in vivo and in vitro studies. Local injection of activin promoted fracture healing in rat fibula fracture models. Since both activin and its receptor are expressed during fracture healing, activin would be involved in the healing process via autocrine and/or paracrine mode of action. Activin was abundantly stored also in normal bone matrix, presumably produced by osteoblasts in the process of normal bone formation. It was observed that activin was released in the culture of neonatal mouse calvaria, and the release was strongly coupled with bone resorption. Thus, activin could be involved in the regulation of bone remodeling as one of coupling factors, as was suggested for TGF-ss. Systemic administration of activin in aged ovariectomized rats, in which bone mass decreases due to uncoupling between bone resorption and formation, increased both bone mass and mechanical strength of vertebral bodies. These findings suggest physiological roles of activin in the regulation of bone formation, and further, its possible usefulness for the therapy of fracture and osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11451590     DOI: 10.1016/s0303-7207(01)00496-8

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  12 in total

Review 1.  Cancer-associated muscle weakness: What's bone got to do with it?

Authors:  David L Waning; Theresa A Guise
Journal:  Bonekey Rep       Date:  2015-05-20

Review 2.  Skeletal complications in cancer patients with bone metastases.

Authors:  Shunsuke Tsuzuki; Sun Hee Park; Matthew R Eber; Christopher M Peters; Yusuke Shiozawa
Journal:  Int J Urol       Date:  2016-08-03       Impact factor: 3.369

Review 3.  Molecular mechanisms of bone metastasis and associated muscle weakness.

Authors:  David L Waning; Theresa A Guise
Journal:  Clin Cancer Res       Date:  2014-03-27       Impact factor: 12.531

Review 4.  The Role of TGFβ in Bone-Muscle Crosstalk.

Authors:  Jenna N Regan; Trupti Trivedi; Theresa A Guise; David L Waning
Journal:  Curr Osteoporos Rep       Date:  2017-02       Impact factor: 5.096

5.  Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.

Authors:  Gaetano Leto; Lorena Incorvaia; Giuseppe Badalamenti; Francesca M Tumminello; Nicola Gebbia; Carla Flandina; Marilena Crescimanno; Giovambattista Rini
Journal:  Clin Exp Metastasis       Date:  2006-07-14       Impact factor: 5.150

Review 6.  Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling.

Authors:  Jenna N Regan; David L Waning; Theresa A Guise
Journal:  Semin Cell Dev Biol       Date:  2015-11-24       Impact factor: 7.727

7.  Role of follistatin in promoting adipogenesis in women.

Authors:  John N Flanagan; Kristina Linder; Niklas Mejhert; Elisabeth Dungner; Kerstin Wahlen; Pauline Decaunes; Mikael Rydén; Peyman Björklund; Stefan Arver; Shalender Bhasin; Anne Bouloumie; Peter Arner; Ingrid Dahlman
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

Review 8.  Understanding cachexia in the context of metastatic progression.

Authors:  Anup K Biswas; Swarnali Acharyya
Journal:  Nat Rev Cancer       Date:  2020-03-31       Impact factor: 60.716

9.  ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass.

Authors:  Rafael Barreto; Yukiko Kitase; Tsutomu Matsumoto; Fabrizio Pin; Kyra C Colston; Katherine E Couch; Thomas M O'Connell; Marion E Couch; Lynda F Bonewald; Andrea Bonetto
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

Review 10.  Bone Regeneration Using Gene-Activated Matrices.

Authors:  Sheetal D'Mello; Keerthi Atluri; Sean M Geary; Liu Hong; Satheesh Elangovan; Aliasger K Salem
Journal:  AAPS J       Date:  2016-09-21       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.